Drug
Linrodostat clinical trials
Also written BMS-986205 and ONO-7701.
- studies test it
- 22
- open now
- 0
- in phase 3
- 3
- first study started
- 2016
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2017 (8)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 8 |
| 2018 | 7 |
| 2019 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 10
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 5
Bristol-Myers Squibb (17) · Memorial Sloan Kettering Cancer Center (1) · Northwestern University (1) · Thomas Jefferson University (1) · Edward Kim (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Nivolumab (7) · Ipilimumab (4) · Relatlimab (3) · Temozolomide (1) · Rucaparib (1) · BMS-813160 (1) · Omeprazole (1) · Itraconazole (1)
Studies
Open first, then newest update. How each study uses linrodostat is read from its arms, and is right about nine times in ten.
Testing it · 22
- Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckTerminatedPhase 2Thomas Jefferson UniversityNCT03854032Written as IDO1 Inhibitor BMS-986205
- Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to TreatmentActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04106414Written as BMS- 986205
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver CancerTerminatedPhase 1/2Edward KimNCT03695250Written as IDO1 Inhibitor BMS-986205
- An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedPhase 1/2Bristol-Myers SquibbNCT03459222Written as BMS-986205
- Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingPhase 1Northwestern UniversityNCT04047706Written as IDO1 Inhibitor BMS-986205 25mg
- A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedPhase 2Bristol-Myers SquibbNCT02935634Written as BMS-986205
- A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderTerminatedPhase 2Bristol-Myers SquibbNCT03519256Written as BMS-986205
- A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCompletedPhase 2Bristol-Myers SquibbNCT02996110Written as BMS-986205
- A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT03792750Written as BMS-986205
- An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced MelanomaCompletedPhase 3Bristol-Myers SquibbNCT03329846Written as BMS-986205
- An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedPhase 2Bristol-Myers SquibbNCT02750514Written as BMS-986205
- A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWithdrawnPhase 2Dana-Farber Cancer InstituteNCT04007588Written as BMS-986205
- A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03936374Written as BMS-986205
- An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and NeckWithdrawnPhase 3Bristol-Myers SquibbNCT03386838Written as BMS-986205
- A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced TumorsCompletedPhase 1Bristol-Myers SquibbNCT03192943Written as BMS-986205
- A Study to Evaluate the Bioavailability of BMS-986205CompletedPhase 1Bristol-Myers SquibbNCT03374228Written as BMS-986205
- An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerWithdrawnPhase 3Bristol-Myers SquibbNCT03417037Written as BMS-986205
- A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference TabletCompletedPhase 1Bristol-Myers SquibbNCT03378310Written as BMS-986205 reference tablet
- A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT03346837Written as BMS-986205
- A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a TabletCompletedPhase 1Bristol-Myers SquibbNCT03362411Written as BMS-986205
See all 22 studies that test linrodostat →
Given in every arm · 1 — linrodostat is usual care beside what is tested
Codes
What other systems call linrodostat · ClinicalTrials.gg INT001068
- MeSH (NLM) C000630574linrodostatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0A7729F42KLINRODOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q29213697linrodostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C141135LinrodostatOne source FDA
- DrugBank DB14986One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630574 | linrodostat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0A7729F42K | LINRODOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q29213697 | linrodostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C141135 | Linrodostat | One source FDA |
| DrugBank | DB14986 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.